{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Avita Medical, Inc."},"Symbol":{"label":"Symbol","value":"RCEL"},"Address":{"label":"Address","value":"28159 AVENUE STANFORD,SUITE 220, VALENCIA, LOS ANGELES, California, 91355, United States"},"Phone":{"label":"Phone","value":"+1 661 367-9170"},"Industry":{"label":"Industry","value":"Medical/Dental Instruments"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 U.S. burn centres. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the U.S. region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022."},"CompanyUrl":{"label":"Company Url","value":"https://www.avitamedical.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"David Fencil","title":"Senior Vice President-Global Operations"},{"name":"James M. Corbett","title":"President, CEO & Executive Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}